The European Commission has granted marketing authorization for caplacizumab for the treatment of adults experiencing an episode of aTTP on August 31, 2018.
Answering TTP Foundation provided research grant funding to support Dr. Long Zheng which has resulted in two research papers on TTP. Together we are furthering the understanding and coming closer to a targeted treatment for TTP. Congratulations Dr. Long Zheng! And congratulations to all supporters of the Answering TTP Foundation.
A healthcare research firm is recruiting patients who have been diagnosed with hereditary (inherited) thrombotic thrombocytopenic purpura (hTTP). hTTP represents about 1% of TTP cases and is characterized by inherited deficiency or abnormality of the ADAMTS 13 enzyme.
For more information and for participation instructions click here.
The 9th Annual Chance for Change raised $200,000 on April 21, 2018. Guests were thrilled by our new venue, our wide selection of silent auction items, the fun games, exciting raffles, stunning entertainment and delicious food.
Listen to the feedback from our guests ----
The Answering TTP Foundation's Board of Directors has received impact statements from two Principal Investigators that have completed their Foundation funded grants. The results are encouraging. A patient-led organization plays a vital role in the quest to conquer TTP. Congratulations to our researchers and to all those who support the Foundation.
More information about these research grant outcomes has been uploaded to each grant information page,
Kelly Ketcham passed from TTP one year ago. Kelly had three young, beautiful girls. She left behind loving family and friends that miss her more than words can say. Her family is organizing this t-shirt fundraiser in Kelly's honour to benefit Answering TTP Foundation.
Our heartfelt condolences to the family of the late Max Marin who died 10 days after being diagnosed with TTP. Max lived in Calgary, Alberta. He was a 45-year-old father, husband and well-known MMA trainer. Reports indicate that the TTP diagnosis was missed by the health clinic he visited initially. Only when his health deteriorated, and his family took him to the main hospital, was he diagnosed with TTP.
A research team at McMaster University has partnered with the International Society on Thrombosis and Haemostatis (ISTH) to create a clinical practice guideline on the diagnosis and management of TTP. The goal is to bring together a panel of expert researchers, clinicians, and patients to develop a set of recommendations on how to diagnose and treat TTP. Ultimately, this guideline will contribute to high quality care for patients with TTP around the world.
A healthcare research continues to recruit patients who have been diagnosed with acquired thrombotic thrombocytopenic purpura (aTTP) and live in the Continental US. This research focuses on understanding your experience with aTTP as well as evaluating a questionnaire designed for use in patients with aTTP. This research may help improve how the patients’ experience is accounted for in clinical trials for new treatments.